Dynavax received U.S. FDA nod for Heplisav-B [Hepatitis B Vaccine (Recombinant), Adjuvanted]

Dynavax received U.S. FDA nod for Heplisav-B [Hepatitis B Vaccine (Recombinant), Adjuvanted]

 

U.S. FDA approved Dynavax drugs Heplisav-B [Hepatitis B Vaccine (Recombinant), Adjuvanted] for the treatment of Hepatitis B.

Company: Dynavax

Specific Treatments: Hepatitis B virus

Therapeutic Areas: Hepatology (Gall Bladder, Pancreatic, Liver), Infections and Infectious Diseases

 

 

General Information of Heplisav-B [Hepatitis B Vaccine (Recombinant), Adjuvanted]

Heplisav-B [Hepatitis B Vaccine (Recombinant), Adjuvanted] combines hepatitis B surface antigen with a proprietary Toll-like Receptor 9 agonist to enhance the immune response.

 

Heplisav-B is specifically indicated for prevention of infection caused by all known subtypes of hepatitis B virus for use in adults 18 years of age and older. 

 

Heplisav-B is supplied as a solution for intramuscular injection. The recommended dose is two doses (0.5 mL each) administered one month apart.

 

Our App

Connect with us

Oddway on facebook Oddway on pinterest Oddway on VK Oddway on LinkedIn Oddway on Twitter

Contact Us

  • icon
    Address : 4216/20, Ground Floor, 1 Ansari Road, Daryaganj,
               New Delhi - 110002 (India)
  • icon
    Phone : +91-11-43526658
    Mobile : +91-9873336444
  • icon
    WhatsApp : +91-9873336444
    Viber          : +91-9873336444

Oddway International is a Pharmaceutical Exporter & Supplier of Generic Medicine and Online Pharmacy Distributor in India...Read More

Top